Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference
Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference
WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside chat at 1:00 PM ET on June 6 at the Jefferies Global Healthcare Conference, taking place June 4-6, 2024, in New York City, New York.
马萨诸塞州沃特敦，2024年5月30日（GLOBE NEWSWIRE）——Werewolf Therapeutics, Inc.（“公司” 或 “狼人”）（纳斯达克股票代码：HOWL）是一家率先开发旨在刺激人体免疫系统以治疗癌症的条件激活疗法的创新生物制药公司，今天宣布，Werewolf总裁兼首席执行官丹尼尔·希克林博士今天宣布，Werewolf总裁兼首席执行官丹尼尔·希克林博士，Werewolf首席医学官兰迪·艾萨克斯医学博士将于美国东部时间6月6日下午1点在杰富瑞全球医疗保健公司参加炉边谈话会议将于2024年6月4日至6日在纽约州纽约市举行。
A live webcast link for the Jefferies Global Healthcare Conference event will be available at An archived replay will be available for approximately 90 days following the event.
杰富瑞全球医疗保健大会活动的网络直播链接将在活动结束后约90天内提供存档重播。
About Werewolf Therapeutics:
关于狼人疗法：
Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. We are leveraging our proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. We expect to advance WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a single agent.
Werewolf Therapeutics, Inc. 是一家创新的生物制药公司，率先开发旨在刺激人体免疫系统的疗法，用于治疗癌症和其他免疫介导疾病。我们正在利用我们专有的PREDATOR平台来设计刺激适应性和先天免疫的条件激活分子，目标是解决传统促炎免疫疗法的局限性。我们的INDUKINE分子旨在在外周组织中保持非活性，但在肿瘤微环境中有选择地激活。我们最先进的临床阶段候选产品 WTX-124 和 WTX-330 分别是系统输送、条件激活的白介素-2（IL-2）和白介素-12（IL-12）INDUKINE分子，用于治疗实体瘤。我们预计将作为单一药物推进多种肿瘤类型的 WTX-124，与免疫检查点抑制剂联合使用，在多种肿瘤类型中推进 WTX-330 或作为单一药物治疗非霍奇金淋巴瘤。
Investor Contact:
Josh Rappaport
Precision AQ
212.362.1200
Josh.Rappaport@precisionaq.com
投资者联系人：
乔什·拉帕波特
精度 AQ
212.362.1200
Josh.Rappaport@precisionaq.com
Amanda Sellers
VERGE Scientific Communications
301.332.5574
asellers@vergescientific.com
阿曼达塞尔斯
VERGE 科学通讯
301.332.5574
asellers@vergescientific.com
Company Contact:
Ellen Lubman
Chief Business Officer
Werewolf Therapeutics
elubman@werewolftx.com
公司联系人：
艾伦·卢布曼
首席商务官
狼人疗法
elubman@werewolftx.com